<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064816</url>
  </required_header>
  <id_info>
    <org_study_id>200136-570</org_study_id>
    <secondary_id>2013-004450-21</secondary_id>
    <nct_id>NCT02064816</nct_id>
  </id_info>
  <brief_title>A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4
      study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a
      lower severity of flu-like symptoms (FLS) as compared to the evening administration, in
      subjects with relapsing multiple sclerosis (RMS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2014</start_date>
  <completion_date type="Actual">April 30, 2016</completion_date>
  <primary_completion_date type="Actual">April 30, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 12 is presented in statistical analysis section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4 and 8</measure>
    <time_frame>Week 4 and 8</time_frame>
    <description>The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 4 and 8 is presented in statistical analysis section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale Scores Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4, 8 and 12</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
    <description>MSTCQ was used as a tool to measure treatment satisfaction, focusing on attributes specific to MS medications. Following sub-scales were assessed: Injection site reactions (ISRs), Global side-effects, Benefits, Pain, Visual Analog Scale (VAS), and Rating of Pain. ISR subscale was defined as sum of scores for questions 17 to 20, with a minimum possible total score of 4 and a maximum possible total score of 20. Global side-effects subscale was defined as sum of scores for questions 21 to 23 with minimum possible total score of 3 and a maximum possible total score of 15. Benefits (question 35); description of pain (question 36); VAS (question 37); rating of pain (question 38) subscales ranged from minimum possible score of 1 and a maximum possible total score of 5. For each of the subscales, lower scores indicated better satisfaction. Difference between both the groups at Week 4, 8 and 12 for individual sub-scales is presented in statistical analysis section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 4, 8 and 12</measure>
    <time_frame>Baseline, Week 4, 8 and 12</time_frame>
    <description>HADS was used to measure depression and anxiety in subjects. The scale was limited to 14 questions. Seven of the items related to anxiety and 7 related to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fatigue Severity Scale (FSS) Score at Week 4, 8 and 12</measure>
    <time_frame>Baseline, Week 4, 8 and 12</time_frame>
    <description>FSS is a method designed to assess disabling fatigue in all the individuals. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each item assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 4, 8 and 12</measure>
    <time_frame>Baseline, Week 4, 8 and 12</time_frame>
    <description>PSQI is a self-rated questionnaire which assess sleep quality and disturbances over a 1-month interval using seven clinically derived components of sleep difficulties: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. PSQI is a summary of 7 components. Each component is scored from 0 to 3, therefore PSQI has a range of 0 (better) to 21 (worse). Interpretation of the PSQI is that a score less than 5 is associated with good sleep quality and a score of 5 or greater is associated with poor sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQOL) Score at Week 4, 8 and 12</measure>
    <time_frame>Baseline, Week 4, 8 and 12</time_frame>
    <description>The MusiQoL is a validated 31-item questionnaire describing 9 dimensions: activities of daily living (8 items); psychological well-being (4 items); symptoms (3 items); relationships with friends (4 items); relationships with family (3 items); relationship with healthcare system (3 items); sentimental and sexual life (2 items); coping (2 items); and rejection (2 items). Each of the questions was answered using a 6-point Likert scale ranging from 1 (never/not at all) to 6 (always/very much). The scores of each dimension were obtained by computing mean of the item scores of dimension with negatively worded item scores reversed so that higher scores indicated higher health-related quality of life (QoL). All 9 dimension scores were linearly transformed to a 0 to 100 scale and the average of the 9 dimensions was used to give a Global Score ranging from 0 to 100, where higher scores indicated higher health-related quality of life (QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Treatment Adherence at Week 4, 8 and 12</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
    <description>Adherence to treatment was calculated as 100 x the number of completed injections the subject administered divided by the expected number of injections. Treatment adherence was divided in two categories: percentage of subjects with less than (&lt;) 80 percent adherence and percentage of subjects with more than or equal to (&gt;=) 80 percent adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Circulating Levels of Cytokines at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Results are presented for three cytokines: leptin, resistin and adiponectin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Change From Baseline in Circulating Levels of Cytokines (Leptin, Resistin and Adiponectin) and in Flu Like Symptom (FLS) Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Correlation was assessed by using Pearson correlation coefficient. The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to MS medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Change From Baseline in Circulating Levels of Cytokines and in Other MSTCQ Items, HADS, FSS, PSQI and MusiQOL Scores at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Correlation was assessed by using Pearson correlation coefficient. MSTCQ, HADS, FSS, PSQI and MusiQOL are described in the above endpoints. Following abbreviations used in the categories: Global side-effects (GLOBSE); description of pain (PAINDESCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cytokines (Leptin and Resistin) Levels at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Results are presented for cytokines: leptin and resistin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cytokine (Adiponectin) Level at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hormone-Like Cytokine (Interleukin-6, 10 and 12) Levels at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Sleep Time (TST) and Rapid Eye Movement (REM) Sleep Time at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Polysomnography (PSG) was performed for subjects who participated in the sub study. PSG is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Change From Baseline in Cytokines (Leptin, Resistin and Adiponectin) and Hormone-like Cytokine Levels (Interleukin-6, 10 and 12), and TST and REM Sleep Time at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Correlations between change from baseline at Week 12 in TST or REM sleep and the area under the curve (AUC) calculated using the trapezoidal method for cytokine levels (i.e., leptin, resistin, adiponectin, Interleukin (IL)-12, IL 10, and IL 6) were analyzed using Pearson's correlation coefficient. Polysomnography (PSG) was performed for subjects who participated in the sub study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Rebif® Morning Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rebif® Evening Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif®</intervention_name>
    <description>Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.</description>
    <arm_group_label>Rebif® Morning Administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif®</intervention_name>
    <description>Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.</description>
    <arm_group_label>Rebif® Evening Administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 18 and 60 years of age

          -  Female subjects must be neither pregnant nor breast-feeding and must lack
             child-bearing potential. Furthermore, female subjects must not have been pregnant from
             at least three months prior to enter in the study

          -  Subjects have RMS according to the revised McDonald Criteria (2010)

          -  Subjects with an expanded disability status scale (EDSS) score of less than 6.0

          -  Subjects naive to treatment and eligible for treatment with Rebif® 44 three times a
             week, or patients having received glatiramer acetate with a wash-out from at least one
             month, or patients having received treatment with natalizumab or fingolimod with a
             wash-out from at least three months

          -  Subjects able to self-inject treatment using RebiSmart®

          -  Subjects willing and able to comply with the protocol for the duration of the study

          -  Subjects have given written informed consent to take part in the study

        Exclusion Criteria:

          -  Subjects have any disease other than MS that could better explain his/her signs and
             symptoms

          -  Subjects who have received any immunosuppressive agents within 3 months prior to
             Baseline

          -  Subjects who have received any corticosteroids within 30 days prior to Baseline

          -  Subjects have a MS relapse within 30 days prior to Baseline

          -  Subjects have inadequate liver function and bone marrow reserve as defined in the
             protocol

          -  Subjects have moderate to severe renal impairment

          -  Subjects have any visual or physical impairment that precludes the subjects from
             self-injecting the treatment using RebiSmart®

          -  Subjects have hypersensitivity to natural or recombinant interferon, or to any of its
             excipients

          -  Subjects have any contra-indications to treatment with interferon (IFN) beta 1a
             according to Summary of Product Characteristics (SmPC)

          -  Subjects have any contra-indications to treatment with ibuprofen/paracetamol according
             to SmPC

          -  Obese subjects, defined by body mass index greater than 30 kilogram per square meter
             (kg/m^2)

          -  Subjects have participated in any other investigational trial within 30 days from
             Baseline

          -  Subjects have any other significant disease that in the Investigator's opinion would
             exclude the subject from the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono S.P.A., Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <results_first_submitted>January 16, 2018</results_first_submitted>
  <results_first_submitted_qc>January 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2018</results_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis, Relapsing-Remitting</keyword>
  <keyword>Interferon beta 1a</keyword>
  <keyword>Rebif®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 29 clinical trial sites in Italy.</recruitment_details>
      <pre_assignment_details>A total of 200 subjects were enrolled in the study, of which 104 were randomized to Rebif morning treatment group, and 96 were randomized to Rebif evening treatment group. A subgroup of subjects also took part in a sub study assessing cytokines and other immunological biomarkers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rebif Morning Administration</title>
          <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Rebif Evening Administration</title>
          <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Therapeutic failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intention to Treat Analysis Set (ITT) included all subjects enrolled into the study and assigned to the RebiSmart device.</population>
      <group_list>
        <group group_id="B1">
          <title>Rebif Morning Administration</title>
          <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Rebif Evening Administration</title>
          <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=18 years to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12</title>
        <description>The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 12 is presented in statistical analysis section.</description>
        <time_frame>Week 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Missing data on FLS were imputed using the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12</title>
          <description>The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 12 is presented in statistical analysis section.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Missing data on FLS were imputed using the last observation carried forward (LOCF) method.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="3.87"/>
                    <measurement group_id="O2" value="11.8" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.277763</p_value>
            <method>Mann-Whitney Non Parametric test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4 and 8</title>
        <description>The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 4 and 8 is presented in statistical analysis section.</description>
        <time_frame>Week 4 and 8</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4 and 8</title>
          <description>The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 4 and 8 is presented in statistical analysis section.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4368" lower_limit="11.7402" upper_limit="13.1333"/>
                    <measurement group_id="O2" value="11.0876" lower_limit="10.3705" upper_limit="11.8046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0039" lower_limit="12.3244" upper_limit="13.6834"/>
                    <measurement group_id="O2" value="11.6672" lower_limit="10.9565" upper_limit="12.3779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0083</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>Least Square (LS) Mean difference</param_type>
            <param_value>1.3492</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3495</ci_lower_limit>
            <ci_upper_limit>2.3489</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>1.3367</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3534</ci_lower_limit>
            <ci_upper_limit>2.3200</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale Scores Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4, 8 and 12</title>
        <description>MSTCQ was used as a tool to measure treatment satisfaction, focusing on attributes specific to MS medications. Following sub-scales were assessed: Injection site reactions (ISRs), Global side-effects, Benefits, Pain, Visual Analog Scale (VAS), and Rating of Pain. ISR subscale was defined as sum of scores for questions 17 to 20, with a minimum possible total score of 4 and a maximum possible total score of 20. Global side-effects subscale was defined as sum of scores for questions 21 to 23 with minimum possible total score of 3 and a maximum possible total score of 15. Benefits (question 35); description of pain (question 36); VAS (question 37); rating of pain (question 38) subscales ranged from minimum possible score of 1 and a maximum possible total score of 5. For each of the subscales, lower scores indicated better satisfaction. Difference between both the groups at Week 4, 8 and 12 for individual sub-scales is presented in statistical analysis section.</description>
        <time_frame>Week 4, 8 and 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale Scores Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4, 8 and 12</title>
          <description>MSTCQ was used as a tool to measure treatment satisfaction, focusing on attributes specific to MS medications. Following sub-scales were assessed: Injection site reactions (ISRs), Global side-effects, Benefits, Pain, Visual Analog Scale (VAS), and Rating of Pain. ISR subscale was defined as sum of scores for questions 17 to 20, with a minimum possible total score of 4 and a maximum possible total score of 20. Global side-effects subscale was defined as sum of scores for questions 21 to 23 with minimum possible total score of 3 and a maximum possible total score of 15. Benefits (question 35); description of pain (question 36); VAS (question 37); rating of pain (question 38) subscales ranged from minimum possible score of 1 and a maximum possible total score of 5. For each of the subscales, lower scores indicated better satisfaction. Difference between both the groups at Week 4, 8 and 12 for individual sub-scales is presented in statistical analysis section.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ISRs subscale Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8459" lower_limit="10.1609" upper_limit="11.5309"/>
                    <measurement group_id="O2" value="10.4456" lower_limit="9.7177" upper_limit="11.1735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISRs subscale Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5363" lower_limit="10.8625" upper_limit="12.2101"/>
                    <measurement group_id="O2" value="11.4515" lower_limit="10.7540" upper_limit="12.1490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISRs subscale Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6380" lower_limit="10.9720" upper_limit="12.3041"/>
                    <measurement group_id="O2" value="11.9625" lower_limit="11.2598" upper_limit="12.6652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global side-effect subscale: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2144" lower_limit="9.6771" upper_limit="10.7518"/>
                    <measurement group_id="O2" value="10.2852" lower_limit="9.7276" upper_limit="10.8429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global side-effect subscale: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4111" lower_limit="9.8698" upper_limit="10.9525"/>
                    <measurement group_id="O2" value="10.2214" lower_limit="9.6567" upper_limit="10.7862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global side-effect subscale: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5879" lower_limit="10.0456" upper_limit="11.1302"/>
                    <measurement group_id="O2" value="10.1782" lower_limit="9.6132" upper_limit="10.7432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benefits: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1325" lower_limit="2.7856" upper_limit="3.4794"/>
                    <measurement group_id="O2" value="3.5408" lower_limit="3.1912" upper_limit="3.8905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benefits: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5779" lower_limit="3.2207" upper_limit="3.9351"/>
                    <measurement group_id="O2" value="3.7137" lower_limit="3.3622" upper_limit="4.0652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benefits: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6059" lower_limit="3.2467" upper_limit="3.9652"/>
                    <measurement group_id="O2" value="3.6640" lower_limit="3.3062" upper_limit="4.0218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Description of pain: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3755" lower_limit="3.2024" upper_limit="5.5485"/>
                    <measurement group_id="O2" value="3.7846" lower_limit="2.5846" upper_limit="4.9847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Description of pain: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3132" lower_limit="4.1262" upper_limit="6.5003"/>
                    <measurement group_id="O2" value="6.0821" lower_limit="4.8767" upper_limit="7.2875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Description of pain: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7853" lower_limit="4.6089" upper_limit="6.9617"/>
                    <measurement group_id="O2" value="5.6431" lower_limit="4.4239" upper_limit="6.8624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8837" lower_limit="7.6691" upper_limit="16.0983"/>
                    <measurement group_id="O2" value="11.2293" lower_limit="6.8280" upper_limit="15.6305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2316" lower_limit="12.9597" upper_limit="21.5035"/>
                    <measurement group_id="O2" value="19.4610" lower_limit="15.0359" upper_limit="23.8860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1757" lower_limit="11.9054" upper_limit="20.4460"/>
                    <measurement group_id="O2" value="21.5953" lower_limit="17.1359" upper_limit="26.0547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rating of pain: Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3073" lower_limit="1.1008" upper_limit="1.5138"/>
                    <measurement group_id="O2" value="1.3004" lower_limit="1.0846" upper_limit="1.5162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rating of pain: Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5653" lower_limit="1.3553" upper_limit="1.7753"/>
                    <measurement group_id="O2" value="1.6522" lower_limit="1.4356" upper_limit="1.8688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rating of pain: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4994" lower_limit="1.2895" upper_limit="1.7094"/>
                    <measurement group_id="O2" value="1.7218" lower_limit="1.5029" upper_limit="1.9407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ISRs subscale Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4311</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>0.4003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5992</ci_lower_limit>
            <ci_upper_limit>1.3998</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ISRs subscale Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8635</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>0.08479</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8850</ci_lower_limit>
            <ci_upper_limit>1.0546</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ISRs subscale Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5099</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.3245</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2927</ci_lower_limit>
            <ci_upper_limit>0.6437</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global side-effect subscale: Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8574</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.07079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8452</ci_lower_limit>
            <ci_upper_limit>0.7036</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global side-effect subscale: Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6338</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>0.1897</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5926</ci_lower_limit>
            <ci_upper_limit>0.9720</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global side-effect subscale: Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3042</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>0.4097</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3734</ci_lower_limit>
            <ci_upper_limit>1.1929</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Benefits: Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1038</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.4083</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9008</ci_lower_limit>
            <ci_upper_limit>0.08419</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Benefits: Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5940</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.1358</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6370</ci_lower_limit>
            <ci_upper_limit>0.3653</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Benefits: Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8217</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.05809</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5651</ci_lower_limit>
            <ci_upper_limit>0.4489</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Description of pain: Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4890</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>0.5909</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0873</ci_lower_limit>
            <ci_upper_limit>2.2690</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Description of pain: Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3719</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.7689</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4607</ci_lower_limit>
            <ci_upper_limit>0.9229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Description of pain: Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8690</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>0.1422</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5521</ci_lower_limit>
            <ci_upper_limit>1.8364</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VAS: Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8328</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>0.6544</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4393</ci_lower_limit>
            <ci_upper_limit>6.7482</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VAS: Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4764</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.2294</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3800</ci_lower_limit>
            <ci_upper_limit>3.9212</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VAS: Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0852</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-5.4196</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.5939</ci_lower_limit>
            <ci_upper_limit>0.7547</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rating of pain: Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9639</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>0.006873</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2918</ci_lower_limit>
            <ci_upper_limit>0.3055</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rating of pain: Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5715</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.08689</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3886</ci_lower_limit>
            <ci_upper_limit>0.2148</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rating of pain: Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1502</p_value>
            <method>linear mixed model for repeated measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.2224</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5256</ci_lower_limit>
            <ci_upper_limit>0.08090</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 4, 8 and 12</title>
        <description>HADS was used to measure depression and anxiety in subjects. The scale was limited to 14 questions. Seven of the items related to anxiety and 7 related to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.</description>
        <time_frame>Baseline, Week 4, 8 and 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 4, 8 and 12</title>
          <description>HADS was used to measure depression and anxiety in subjects. The scale was limited to 14 questions. Seven of the items related to anxiety and 7 related to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety score: Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6625" lower_limit="-1.1976" upper_limit="-0.1273"/>
                    <measurement group_id="O2" value="-0.4604" lower_limit="-1.0106" upper_limit="0.08968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety score: Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7222" lower_limit="-1.2688" upper_limit="-0.1755"/>
                    <measurement group_id="O2" value="-0.3763" lower_limit="-0.9308" upper_limit="0.1782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety score: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6435" lower_limit="-1.1879" upper_limit="-0.09918"/>
                    <measurement group_id="O2" value="0.05023" lower_limit="-0.5081" upper_limit="0.6085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression score: Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1539" lower_limit="-0.8083" upper_limit="0.5005"/>
                    <measurement group_id="O2" value="0.2211" lower_limit="-0.4617" upper_limit="0.9038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression score: Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2397" lower_limit="-0.9062" upper_limit="0.4267"/>
                    <measurement group_id="O2" value="0.1999" lower_limit="-0.4835" upper_limit="0.8833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression score: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1906" lower_limit="-0.4778" upper_limit="0.8590"/>
                    <measurement group_id="O2" value="0.1162" lower_limit="-0.5741" upper_limit="0.8066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fatigue Severity Scale (FSS) Score at Week 4, 8 and 12</title>
        <description>FSS is a method designed to assess disabling fatigue in all the individuals. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each item assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.</description>
        <time_frame>Baseline, Week 4, 8 and 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fatigue Severity Scale (FSS) Score at Week 4, 8 and 12</title>
          <description>FSS is a method designed to assess disabling fatigue in all the individuals. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each item assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2089" lower_limit="-0.05810" upper_limit="0.4759"/>
                    <measurement group_id="O2" value="0.06901" lower_limit="-0.2010" upper_limit="0.3391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2062" lower_limit="-0.06211" upper_limit="0.4746"/>
                    <measurement group_id="O2" value="0.1366" lower_limit="-0.1354" upper_limit="0.4085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1464" lower_limit="-0.1253" upper_limit="0.4182"/>
                    <measurement group_id="O2" value="0.1942" lower_limit="-0.08036" upper_limit="0.4688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 4, 8 and 12</title>
        <description>PSQI is a self-rated questionnaire which assess sleep quality and disturbances over a 1-month interval using seven clinically derived components of sleep difficulties: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. PSQI is a summary of 7 components. Each component is scored from 0 to 3, therefore PSQI has a range of 0 (better) to 21 (worse). Interpretation of the PSQI is that a score less than 5 is associated with good sleep quality and a score of 5 or greater is associated with poor sleep quality.</description>
        <time_frame>Baseline, Week 4, 8 and 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 4, 8 and 12</title>
          <description>PSQI is a self-rated questionnaire which assess sleep quality and disturbances over a 1-month interval using seven clinically derived components of sleep difficulties: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. PSQI is a summary of 7 components. Each component is scored from 0 to 3, therefore PSQI has a range of 0 (better) to 21 (worse). Interpretation of the PSQI is that a score less than 5 is associated with good sleep quality and a score of 5 or greater is associated with poor sleep quality.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08889" lower_limit="-0.7690" upper_limit="0.5912"/>
                    <measurement group_id="O2" value="0.5747" lower_limit="-0.1653" upper_limit="1.3147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="62"/>
                    <count group_id="O2" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4513" lower_limit="-1.1161" upper_limit="0.2136"/>
                    <measurement group_id="O2" value="0.7092" lower_limit="-0.01588" upper_limit="1.4343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07841" lower_limit="-0.6265" upper_limit="0.7833"/>
                    <measurement group_id="O2" value="0.4293" lower_limit="-0.3270" upper_limit="1.1855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQOL) Score at Week 4, 8 and 12</title>
        <description>The MusiQoL is a validated 31-item questionnaire describing 9 dimensions: activities of daily living (8 items); psychological well-being (4 items); symptoms (3 items); relationships with friends (4 items); relationships with family (3 items); relationship with healthcare system (3 items); sentimental and sexual life (2 items); coping (2 items); and rejection (2 items). Each of the questions was answered using a 6-point Likert scale ranging from 1 (never/not at all) to 6 (always/very much). The scores of each dimension were obtained by computing mean of the item scores of dimension with negatively worded item scores reversed so that higher scores indicated higher health-related quality of life (QoL). All 9 dimension scores were linearly transformed to a 0 to 100 scale and the average of the 9 dimensions was used to give a Global Score ranging from 0 to 100, where higher scores indicated higher health-related quality of life (QoL).</description>
        <time_frame>Baseline, Week 4, 8 and 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQOL) Score at Week 4, 8 and 12</title>
          <description>The MusiQoL is a validated 31-item questionnaire describing 9 dimensions: activities of daily living (8 items); psychological well-being (4 items); symptoms (3 items); relationships with friends (4 items); relationships with family (3 items); relationship with healthcare system (3 items); sentimental and sexual life (2 items); coping (2 items); and rejection (2 items). Each of the questions was answered using a 6-point Likert scale ranging from 1 (never/not at all) to 6 (always/very much). The scores of each dimension were obtained by computing mean of the item scores of dimension with negatively worded item scores reversed so that higher scores indicated higher health-related quality of life (QoL). All 9 dimension scores were linearly transformed to a 0 to 100 scale and the average of the 9 dimensions was used to give a Global Score ranging from 0 to 100, where higher scores indicated higher health-related quality of life (QoL).</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>units on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Global Score: Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6283" lower_limit="-0.3761" upper_limit="3.6326"/>
                    <measurement group_id="O2" value="0.1174" lower_limit="-1.9196" upper_limit="2.1544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Score: Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1439" lower_limit="-0.8780" upper_limit="3.1658"/>
                    <measurement group_id="O2" value="-2.2945" lower_limit="-4.3568" upper_limit="-0.2321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Score: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9670" lower_limit="-1.0753" upper_limit="3.0094"/>
                    <measurement group_id="O2" value="-1.3948" lower_limit="-3.4796" upper_limit="0.6900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Treatment Adherence at Week 4, 8 and 12</title>
        <description>Adherence to treatment was calculated as 100 x the number of completed injections the subject administered divided by the expected number of injections. Treatment adherence was divided in two categories: percentage of subjects with less than (&lt;) 80 percent adherence and percentage of subjects with more than or equal to (&gt;=) 80 percent adherence.</description>
        <time_frame>Week 4, 8 and 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Treatment Adherence at Week 4, 8 and 12</title>
          <description>Adherence to treatment was calculated as 100 x the number of completed injections the subject administered divided by the expected number of injections. Treatment adherence was divided in two categories: percentage of subjects with less than (&lt;) 80 percent adherence and percentage of subjects with more than or equal to (&gt;=) 80 percent adherence.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 80 percent adherence at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 80 percent adherence at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                    <measurement group_id="O2" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 80 percent adherence at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 80 percent adherence at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 80 percent adherence at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 80 percent adherence at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2"/>
                    <measurement group_id="O2" value="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Circulating Levels of Cytokines at Week 12</title>
        <description>Results are presented for three cytokines: leptin, resistin and adiponectin.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Circulating Levels of Cytokines at Week 12</title>
          <description>Results are presented for three cytokines: leptin, resistin and adiponectin.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>microgram per liter (mcg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leptin: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="3.42"/>
                    <measurement group_id="O2" value="-2.6" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="3.31"/>
                    <measurement group_id="O2" value="-3.0" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="6.38"/>
                    <measurement group_id="O2" value="2.8" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Change From Baseline in Circulating Levels of Cytokines (Leptin, Resistin and Adiponectin) and in Flu Like Symptom (FLS) Score at Week 12</title>
        <description>Correlation was assessed by using Pearson correlation coefficient. The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to MS medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Change From Baseline in Circulating Levels of Cytokines (Leptin, Resistin and Adiponectin) and in Flu Like Symptom (FLS) Score at Week 12</title>
          <description>Correlation was assessed by using Pearson correlation coefficient. The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to MS medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction.</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leptin and FLS: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08822"/>
                    <measurement group_id="O2" value="0.03944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and FLS: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20200"/>
                    <measurement group_id="O2" value="-0.01069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and FLS: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04616"/>
                    <measurement group_id="O2" value="-0.13571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Change From Baseline in Circulating Levels of Cytokines and in Other MSTCQ Items, HADS, FSS, PSQI and MusiQOL Scores at Week 12</title>
        <description>Correlation was assessed by using Pearson correlation coefficient. MSTCQ, HADS, FSS, PSQI and MusiQOL are described in the above endpoints. Following abbreviations used in the categories: Global side-effects (GLOBSE); description of pain (PAINDESCR).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Change From Baseline in Circulating Levels of Cytokines and in Other MSTCQ Items, HADS, FSS, PSQI and MusiQOL Scores at Week 12</title>
          <description>Correlation was assessed by using Pearson correlation coefficient. MSTCQ, HADS, FSS, PSQI and MusiQOL are described in the above endpoints. Following abbreviations used in the categories: Global side-effects (GLOBSE); description of pain (PAINDESCR).</description>
          <population>The ITT included all subjects enrolled into the study and assigned to the RebiSmart device. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>Correlation Coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leptin and MSTCQ-ISR: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00595"/>
                    <measurement group_id="O2" value="-0.10214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and MSTCQ-ISR: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22380"/>
                    <measurement group_id="O2" value="0.04855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and MSTCQ-ISR: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13365"/>
                    <measurement group_id="O2" value="-0.14865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and MSTCQ-GLOBSE: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03121"/>
                    <measurement group_id="O2" value="0.21425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and MSTCQ-GLOBSE: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20285"/>
                    <measurement group_id="O2" value="-0.12730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and MSTCQ-GLOBSE: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00169"/>
                    <measurement group_id="O2" value="-0.06398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and MSTCQ-benefits: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13023"/>
                    <measurement group_id="O2" value="-0.10915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and MSTCQ-benefits: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13544"/>
                    <measurement group_id="O2" value="-0.15636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and MSTCQ-benefits: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10726"/>
                    <measurement group_id="O2" value="0.04081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and MSTCQ-PAINDESCR: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09118"/>
                    <measurement group_id="O2" value="0.01165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and MSTCQ-PAINDESCR: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13918"/>
                    <measurement group_id="O2" value="0.04150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and MSTCQ-PAINDESCR: Week12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07093"/>
                    <measurement group_id="O2" value="0.01535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and MSTCQ-VAS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34840"/>
                    <measurement group_id="O2" value="-0.01433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and MSTCQ-VAS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15231"/>
                    <measurement group_id="O2" value="0.16220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and MSTCQ-VAS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07840"/>
                    <measurement group_id="O2" value="0.02109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and MSTCQ-pain rating: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16675"/>
                    <measurement group_id="O2" value="-0.14381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and MSTCQ-pain rating: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23531"/>
                    <measurement group_id="O2" value="0.12355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and MSTCQ-pain rating: Week12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08060"/>
                    <measurement group_id="O2" value="-0.08718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and HADS-anxiety: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00754"/>
                    <measurement group_id="O2" value="-0.06360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and HADS-anxiety: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02447"/>
                    <measurement group_id="O2" value="0.07986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and HADS-anxiety: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06295"/>
                    <measurement group_id="O2" value="0.08818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and HADS-depression: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05226"/>
                    <measurement group_id="O2" value="-0.14953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and HADS-depression: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01970"/>
                    <measurement group_id="O2" value="-0.04154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and HADS-depression: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03228"/>
                    <measurement group_id="O2" value="0.19209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and FSS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04256"/>
                    <measurement group_id="O2" value="0.14284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and FSS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23755"/>
                    <measurement group_id="O2" value="-0.10961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and FSS: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00326"/>
                    <measurement group_id="O2" value="0.03090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and PSQI: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00873"/>
                    <measurement group_id="O2" value="0.00099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and PSQI: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03765"/>
                    <measurement group_id="O2" value="0.12085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and PSQI: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25795"/>
                    <measurement group_id="O2" value="0.24406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin and MusiQoL- Global: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25650"/>
                    <measurement group_id="O2" value="0.17917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin and MusiQoL-Global: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12190"/>
                    <measurement group_id="O2" value="0.21936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin and MusiQoL-Global: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07152"/>
                    <measurement group_id="O2" value="-0.05924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cytokines (Leptin and Resistin) Levels at Week 12</title>
        <description>Results are presented for cytokines: leptin and resistin.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The Sub study Analysis Set (SSAS) included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cytokines (Leptin and Resistin) Levels at Week 12</title>
          <description>Results are presented for cytokines: leptin and resistin.</description>
          <population>The Sub study Analysis Set (SSAS) included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>Nanogram/milliliter (ng/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leptin: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7826" lower_limit="-6.1880" upper_limit="0.6227"/>
                    <measurement group_id="O2" value="-0.7936" lower_limit="-4.4371" upper_limit="2.8499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin: Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6628" lower_limit="-5.3424" upper_limit="-1.9831"/>
                    <measurement group_id="O2" value="-5.8360" lower_limit="-7.6339" upper_limit="-4.0381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cytokine (Adiponectin) Level at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The SSAS included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cytokine (Adiponectin) Level at Week 12</title>
          <population>The SSAS included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7093" lower_limit="-1.0663" upper_limit="6.4848"/>
                    <measurement group_id="O2" value="4.3574" lower_limit="0.3174" upper_limit="8.3975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hormone-Like Cytokine (Interleukin-6, 10 and 12) Levels at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The SSAS included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hormone-Like Cytokine (Interleukin-6, 10 and 12) Levels at Week 12</title>
          <population>The SSAS included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>Pico gram/milliliter (pg/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interleukin-6: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5173" lower_limit="-1.7940" upper_limit="0.7593"/>
                    <measurement group_id="O2" value="-0.6970" lower_limit="-2.0624" upper_limit="0.6683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-10: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05819" lower_limit="-0.5453" upper_limit="0.4290"/>
                    <measurement group_id="O2" value="-0.6660" lower_limit="-1.2999" upper_limit="-0.03210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-12: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3490" lower_limit="-0.9115" upper_limit="0.2135"/>
                    <measurement group_id="O2" value="-0.4384" lower_limit="-0.9973" upper_limit="0.1204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Sleep Time (TST) and Rapid Eye Movement (REM) Sleep Time at Week 12</title>
        <description>Polysomnography (PSG) was performed for subjects who participated in the sub study. PSG is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The SSAS included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Sleep Time (TST) and Rapid Eye Movement (REM) Sleep Time at Week 12</title>
          <description>Polysomnography (PSG) was performed for subjects who participated in the sub study. PSG is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.</description>
          <population>The SSAS included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Sleep Time: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="-73.0" upper_limit="117.0"/>
                    <measurement group_id="O2" value="33.0" lower_limit="-227.0" upper_limit="165.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM sleep: Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-207.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="-67.0" upper_limit="288.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Change From Baseline in Cytokines (Leptin, Resistin and Adiponectin) and Hormone-like Cytokine Levels (Interleukin-6, 10 and 12), and TST and REM Sleep Time at Week 12</title>
        <description>Correlations between change from baseline at Week 12 in TST or REM sleep and the area under the curve (AUC) calculated using the trapezoidal method for cytokine levels (i.e., leptin, resistin, adiponectin, Interleukin (IL)-12, IL 10, and IL 6) were analyzed using Pearson's correlation coefficient. Polysomnography (PSG) was performed for subjects who participated in the sub study.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The SSAS included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Change From Baseline in Cytokines (Leptin, Resistin and Adiponectin) and Hormone-like Cytokine Levels (Interleukin-6, 10 and 12), and TST and REM Sleep Time at Week 12</title>
          <description>Correlations between change from baseline at Week 12 in TST or REM sleep and the area under the curve (AUC) calculated using the trapezoidal method for cytokine levels (i.e., leptin, resistin, adiponectin, Interleukin (IL)-12, IL 10, and IL 6) were analyzed using Pearson's correlation coefficient. Polysomnography (PSG) was performed for subjects who participated in the sub study.</description>
          <population>The SSAS included all subjects in the ITT who were enrolled in the sub study. Here, &quot;Number of Subjects Analyzed&quot; signifies those subjects who were evaluable for this outcome measure. Here &quot;Number Analyzed&quot; signifies those subjects who were evaluable for this outcome measure for specified category.</population>
          <units>Correlation Coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC Leptin and TST: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10816"/>
                    <measurement group_id="O2" value="0.46984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC Resistin and TST: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56278"/>
                    <measurement group_id="O2" value="-0.05056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC Adiponectin and TST: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17402"/>
                    <measurement group_id="O2" value="0.58181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC IL-12 and TST: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44328"/>
                    <measurement group_id="O2" value="0.24717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC IL-10 and TST: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00000"/>
                    <measurement group_id="O2" value="NA">Correlation Coefficient could not be estimated as there was only 1 subject analyzed for this arm at the specified time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC IL-6 and TST: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18626"/>
                    <measurement group_id="O2" value="-0.51662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC Leptin and REM: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99732"/>
                    <measurement group_id="O2" value="0.63155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC Resistin and REM: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22684"/>
                    <measurement group_id="O2" value="-0.38234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC Adiponectin and REM: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98335"/>
                    <measurement group_id="O2" value="-0.05732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC IL-12 and REM: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00000"/>
                    <measurement group_id="O2" value="-0.76606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC IL-10 and REM: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00000"/>
                    <measurement group_id="O2" value="NA">Correlation Coefficient could not be estimated as there was only 1 subject analyzed for this arm at the specified time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC IL-6 and REM: Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06269"/>
                    <measurement group_id="O2" value="-0.34860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug.</description>
        <time_frame>Baseline up to Week 12</time_frame>
        <population>The Safety Analysis Set (SAF) included all subjects in the ITT who received at least 1 dose of the planned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Rebif Morning Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rebif Evening Administration</title>
            <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug.</description>
          <population>The Safety Analysis Set (SAF) included all subjects in the ITT who received at least 1 dose of the planned study treatment.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 12</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rebif Morning Administration</title>
          <description>Subjects self-injected Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using RebiSmart autoinjector device in the morning for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Rebif Evening Administration</title>
          <description>Subjects self-injected Rebif at a dose of 44 mcg subcutaneously three times a week by using RebiSmart autoinjector device in the evening for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Healthcare, a business of Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

